Αρχική World News Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in... World News Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Από Ogkologos - 7 Σεπτεμβρίου, 2026 131 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-671 study after 5 years of follow-up Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Approximately 1 Million of New Maternal Orphans Due to Cancer in... 28 Νοεμβρίου, 2022 Panitumumab Added to Infusional Fluorouracil Plus Leucovorin May Be a Reasonable... 21 Αυγούστου, 2023 Researchers Find a Way to Prevent Cancer Cells from Taking in... 14 Ιουλίου, 2020 Coping With War and Cancer: How to Take Care of Your... 11 Μαρτίου, 2022 Φόρτωση περισσοτέρων HOT NEWS OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and... Addressing Mental Health Needs of Adolescent and Young Adult Cancer Survivors Keeping progress in oncology on the agenda: ESMO honours recipients of... 10 Ways the Inflation Reduction Act will Impact Cancer Care
